menu
    • menu

    Company profile for TIXiMED

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    TIXiMED is focused on developing and commercializing innovative TXNIP-inhibiting therapies as the first oral treatment for Type 1 and Type 2 Diabetes. By targeting TXNIP, a key protein involved in glucose regulation, TIXiMED aims to improve insulin function and restore balance in diabetic patients. Their groundbreaking approach offers a promising alternative to current therapies, with the potential to transform diabetes care a...
    TIXiMED is focused on developing and commercializing innovative TXNIP-inhibiting therapies as the first oral treatment for Type 1 and Type 2 Diabetes. By targeting TXNIP, a key protein involved in glucose regulation, TIXiMED aims to improve insulin function and restore balance in diabetic patients. Their groundbreaking approach offers a promising alternative to current therapies, with the potential to transform diabetes care and provide better outcomes for millions of patients worldwide.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    TIXiMEDUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1927 First Avenue North Birmingham, AL 35203
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://tiximed.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    TIXiMED Expands Helmsley Charitable Trust Investment Program
    TIXiMED Expands Helmsley Charitable Trust Investment Program

    13 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-13/tiximed-announces-expansion-of-program-related-investment-from-the-helmsley-charitable-trust

    PHARMIWEB
    13 Mar 2026
    Share Share
    TIXiMED Reveals Oral TIX100 Prevents Weight Regain Post GLP-1
    TIXiMED Reveals Oral TIX100 Prevents Weight Regain Post GLP-1

    10 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-10/tiximed-announces-promising-preclinical-data-oral-tix100-prevents-weight-regain-after-glp-1-cessati

    PHARMIWEB
    10 Mar 2026
    Share Share
    TIXiMED Completes Phase 1 Study of Oral Type 1 Diabetes Therapy
    TIXiMED Completes Phase 1 Study of Oral Type 1 Diabetes Therapy

    29 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250529307401/en/TIXiMED-Announces-Successful-Completion-of-a-Phase-1-Study-of-its-Novel-Oral-Disease-Modifying-Type-1-Diabetes-Therapy

    BUSINESSWIRE
    29 May 2025
    Share Share
    TIXiMED Doses First Cohort In Ph 1 Trial For Type 1 Diabetes
    TIXiMED Doses First Cohort In Ph 1 Trial For Type 1 Diabetes

    27 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250227506831/en

    BUSINESSWIRE
    27 Feb 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search